Seer, Inc. (SEER)

US — Healthcare Sector
Peers: ORIC  ANEB  CGEM  CCCC  MOLN  MLYS  ANTX  PHVS  PEPG  FHTX  STTK  GLUE  KYMR  NRIX  QSI  HCWB  MNOV  NKTX  LYEL  GBIO  SANA 

Automate Your Wheel Strategy on SEER

With Tiblio's Option Bot, you can configure your own wheel strategy including SEER - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SEER
  • Rev/Share 0.2553
  • Book/Share 5.235
  • PB 0.3668
  • Debt/Equity 0.0817
  • CurrentRatio 19.3443
  • ROIC -0.2849

 

  • MktCap 112984744.0
  • FreeCF/Share -0.851
  • PFCF -2.2349
  • PE -1.3284
  • Debt/Assets 0.0732
  • DivYield 0
  • ROE -0.2548

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 5
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

After Plunging -16.81% in 4 Weeks, Here's Why the Trend Might Reverse for Seer (SEER)
SEER
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Negative

Seer (SEER) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Read More
image for news After Plunging -16.81% in 4 Weeks, Here's Why the Trend Might Reverse for Seer (SEER)
Down -10.53% in 4 Weeks, Here's Why Seer (SEER) Looks Ripe for a Turnaround
SEER
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Positive

The heavy selling pressure might have exhausted for Seer (SEER) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Read More
image for news Down -10.53% in 4 Weeks, Here's Why Seer (SEER) Looks Ripe for a Turnaround
Seer, Inc. (SEER) Q4 2024 Earnings Call Transcript
SEER
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral

Seer, Inc. (NASDAQ:SEER ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Carrie Mendivil - Investor Relations Omid Farokhzad - Chief Executive Officer and Chair of the Board David Horn - Chief Financial Officer and President Conference Call Participants Marta Zaremba - JPMorgan Jason Lai - Morgan Stanley Operator Good day and thank you for standing by. Welcome to the Seer Fourth Quarter and Full-Year 2024 Earnings Conference Call.

Read More
image for news Seer, Inc. (SEER) Q4 2024 Earnings Call Transcript
Seer, Inc. (SEER) Reports Q4 Loss, Tops Revenue Estimates
SEER
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Negative

Seer, Inc. (SEER) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.28 per share a year ago.

Read More
image for news Seer, Inc. (SEER) Reports Q4 Loss, Tops Revenue Estimates
Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025
SEER
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral

Seminar from Dr. Jinjun Shi from Brigham and Women's Hospital and Harvard Medical School to highlight study of proteomic perturbations resulting from a novel approach to cancer therapy revealed using Seer's Proteographâ„¢ Product Suite Seminar from Dr. Jinjun Shi from Brigham and Women's Hospital and Harvard Medical School to highlight study of proteomic perturbations resulting from a novel approach to cancer therapy revealed using Seer's Proteographâ„¢ Product Suite

Read More
image for news Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025

About Seer, Inc. (SEER)

  • IPO Date 2020-12-04
  • Website https://seer.bio
  • Industry Biotechnology
  • CEO Dr. Omid C. Farokhzad M.D., Ph.D.
  • Employees 134

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.